| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d07a4ddba85ae3e35ca0a6f85dad9f6d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 |
| filingDate |
2020-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe7b9d9410d277adcc30536fa2f58344
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a5e19b78e8b54f2941e0ab30ed1496d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_015c7e57782bde06e5f089c9af29bf18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5b2b35938765bfcb82fc03f7b82f04f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea24300775690390986384d46973d67c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23c0b9c127a1f687f4be52d5aa421d33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b32a0459618c67ada5e7f814a017a40c |
| publicationDate |
2021-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2021261554-A1 |
| titleOfInvention |
Ripk2 inhibitors and method of treating cancer with same |
| abstract |
The invention is a compound represented by Structural Formula (I):or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I). |
| priorityDate |
2014-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |